The fibroblast growth factor, FGF8, has been shown to be essential for vertebrate cardiovascular, craniofacial, brain and limb development. Here we report that Fgf8 function is required for normal progression through the late fetal stages of lung development that culminate in alveolar formation. Budding, lobation and branching morphogenesis are unaffected in early stage Fgf8 hypomorphic and conditional mutant lungs. Excess proliferation during fetal development disrupts distal airspace formation, mesenchymal and vascular remodeling, and Type I epithelial cell differentiation resulting in postnatal respiratory failure and death. Our findings reveal a previously unknown, critical role for Fgf8 function in fetal lung development and suggest that this factor may also contribute to postnatal alveologenesis. Given the high number of premature infants with alveolar dysgenesis and lung dysplasia, and the accumulating evidence that short-term benefits of available therapies may be outweighed by long-term detrimental effects on postnatal alveologenesis, the therapeutic implications of identifying a factor or pathway that can be targeted to stimulate normal alveolar development are profound.
Introduction
We previously reported that 100% of Fgf8 deficient newborn mice die in the first postnatal day with cyanosis and respiratory failure (Frank et al., 2002) . Since only 40% of these mutants have predictably lethal cardiovascular defects, our observations led us to hypothesize that pulmonary dysfunction due to abnormal prenatal lung development may cause respiratory failure and death in these animals, and here we report our studies confirming this hypothesis.
Correct progression through embryonic, pseudoglandular, canalicular, and saccular stages of prenatal lung development culminates in alveolar formation after birth, and these stages of lung development are conserved in many vertebrates (Alcorn et al., 1981; Davies et al., 1988; Docimo et al., 1991) . During the embryonic stage, lung development is initiated when the primitive foregut endoderm (epithelium) is induced to invade the surrounding splanchnic mesoderm (mesenchyme) and form the trachea and the bronchi at embryonic day (E) 9.5 in the mouse. The proximal airways form by branching morphogenesis during the embryonic (~E10.5-14.5) and pseudoglandular stages (E14-16.5 in mouse) (Metzger et al., 2008) . The canalicular stage (E16-17.5) is characterized by creation of the pulmonary acinus (air sac), and the multiplication and canalization of capillaries. During the saccular stage (E17-19), peripheral airways form terminal clusters of potential air spaces, and the capillary network and septal cores are remodeled in preparation for gas exchange at birth. In humans, the alveolar phase of lung development normally begins in utero during the final weeks of development and continues postnatally (Boyden, 1974; Davies and Reid, 1970; Emery and Wilcock, 1966; Langston et al., 1984) , whereas in the mouse, alveolarization is predominantly a postnatal event. Alveolar formation is manifest structurally by the protrusion of partitions from saccular walls (Burri, 1997; Schittny et al., 1998) and subsequent elongation of those partitions into secondary septa with accompanying capillaries. Although septal thinning has been attributed to prenatal mesenchymal apoptosis in rabbits and rats (Bruce et al., 1999) , attenuation of the septal mesenchymal core in mice appears to be primarily due to elongation and remodeling of the septa prenatally and via apoptosis postnatally, because very little apoptosis is present in the mouse lung at fetal stages (Bird et al., 2007; Muglia et al., 1999; our unpublished observations) .
The mechanisms that regulate initial budding, branching morphogenesis and proximal airway development have been intensely studied. However, late initiation and prolonged duration of alveolar formation pose significant challenges to identifying the genetic and molecular mechanisms that regulate the late stage lung development (Boyden, 1974; Burri, 1997; Davies and Reid, 1970; Dunnill, 1962; Emery and Wilcock, 1966; Langston et al., 1984) . Mouse knockout models have identified many molecules that regulate embryonic lung development (Colvin et al., 2001; Lindahl et al., 1997) , but this approach often profoundly affects the earliest stages, and pulmonary development ceases and/or death occurs prior to the initiation of the saccular and alveolar stages.
FGF signaling proteins regulate multiple morphogenetic processes during vertebrate organogenesis (Szebenyi and Fallon, 1999) . FGF receptors (FgfRs) are transmembrane tyrosine kinases. Ligand binding induces receptor dimerization, autophosphorylation, intracellular signaling cascades and ultimately, altered gene expression and cell behavior. Several Fgfs and all known FgfRs (FgfR1-5) are expressed in the lung (Bellusci et al., 1997; Colvin et al., 1999; Hu et al., 1998; Powell et al., 1998; Sannes et al., 1992) .
The temporospatial expression of FGF ligands and receptors varies with developmental stage. Fgf10 and Fgf7 are expressed in lung mesenchyme while Fgf1, Fgf9, and Fgf18 are expressed in both mesenchyme and epithelia. Fgf8 transcripts have been detected in embryonic mouse and adult rat lung (Lin et al., 2002; Schmitt et al., 1996) ; however expression of Fgf8 in fetal and postnatal mouse lung has not previously been described. Germline ablation of some Fgf ligands and their receptors has established a central role of reciprocal epithelial/ mesenchymal FGF signaling during the embryonic and pseudoglandular stages (Arman et al., 1999; Bellusci et al., 1997; Cardoso, 2001; Warburton et al., 1999) , but no FGFs have yet been discovered to function during the fetal stages. Targeted deletion of either Fgf10 or its receptor, FgfR2b, inhibits budding of the lung from the trachea (De Moerlooze et al., 2000; Min et al., 1998; Sekine et al., 1999) whereas later embryonic ablation disrupts branching morphogenesis (Abler et al., 2009) . FGF9 stimulates mesenchymal proliferation and propagation of branching in part via stimulating Fgf10 (Colvin et al., 2001) . FGF7 stimulates proliferation and differentiation of distal lung in culture (Cardoso, 2001) , but Fgf7-null mice have normal lung morphology (Guo et al., 1996) . Fgf18 null mutants have lung hypoplasia and decreased fibroblast proliferation during the canalicular stage but normal distal epithelial differentiation (Usui et al., 2004) .
Although data are somewhat conflicting (Celli et al., 1998; Hokuto et al., 2003; Weinstein et al., 1998; Yi et al., 2006) , the overall body of literature suggests that the fetal saccular to alveolar transition and postnatal lung development are FGF-dependent processes, however, no FGF ligands have previously been tested by conditional loss-offunction sufficiently late in lung development to establish which, if any, are required for saccular or alveolar development.
Here we report that Fgf8 has unique required functions to support fetal lung development and may play a role in postnatal alveologenesis. Our data indicate that FGF8 is required to regulate proliferation in the fetal stages; in the absence of adequate Fgf8 function, there is pronounced excess proliferation in both the epithelial and mesenchymal compartments from E16.5 to 18.5 and subsequent disruption of epithelial differentiation and abnormal septal and vascular remodeling.
Materials and methods

Mice
The Fgf8 null (Moon and Capecchi, 2000) , hypomorphic (Frank et al., 2002) and conditional (Park et al., 2006) alleles are as previously described and are maintained in 50% each C57Bl6 and SV129 background. The Isl1Cre allele (Park et al., 2006) is in a 50% C57Bl6 and 25% each BlSw and Sv129 background, and the MesP1Cre allele (Saga et al., 1999) is 50% C57Bl6 and 25% each ICR and SV129.
Lung wet/dry weight ratios
Lung wet/dry weight ratios were determined by use of the microwave drying technique (Peterson et al., 1982) . Briefly, the lungs were freshly excised and the wet weight determined. The tissues were dried in a microwave oven at 200 W for 1 h and then weighed; they were returned to the oven at 5 minute intervals and re-weighed to determine when desiccation was complete and the final measurement used as the dry weight.
Preparation of RNA and cDNA for microarray and microarray data analyses E18.5 lung lobes were dissected away from large airways and vessels and stored in RLT buffer (Qiagen) at −80°C. Three specimens of each genotype (Fgf8 +/+ , controls; Fgf8 H/− , hypomorphic mutants) were pooled to generate each sample. Total RNA was extracted from four samples (RNeasy Micro Kit, Qiagen). This experiment was run in quadruplicate on Agilent mouse whole-genome expression arrays. Agilent two-color LRILAK labeling, the Agilent two-color GE hybridization/wash protocol, and the Agilent 5-micron XDR scanning protocols were carried out by the University of Utah Microarray Core Facility. The array image data were quantitated using Agilent Feature Extraction software (version 9.5.1.1). Subtle intensitydependent bias was corrected with LOWESS normalization, with no background subtraction. The raw and normalized data sets have been submitted to GEO (accession number: gse22893). Spots with intensity below background were removed prior to statistical analysis. Statistical analysis of normalized log-transformed data was performed in GeneSifter (www.genesifter.net). Differentially expressed transcripts were defined (adjusted for multiple testing using the Benjamini and Hochberg method) as P b 0.05. Data were hierarchically clustered with Spotfire (TIBCO) and heat maps for selected genes were generated. For qRT-PCR validation, total RNA from each of the initial four pools (100 ng) was reverse transcribed to cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen). Quantitative RT-PCR was performed with iQ SYBR Green Supermix on the iCycler system (Bio-Rad) and normalization was to hprt, gapdh and βactin. Primer sequences will be provided on request.
Real-time quantitative RT-PCR of Fgf8 and Fgf10 transcripts in wild type lungs
Total RNA was isolated from 5 to 12 pooled lung homogenates from E11.5 to P5 mice using TriZol reagent (Invitrogen, 15596-026). After DNase treatment (Qiagen, 79254), RNA was further purified using the RNAeasy MinElute Cleanup kit (Qiagen, 74204). cDNA templates for PCR amplification were synthesized from 2 μg of total RNA using a SuperScript® III First-Strand Synthesis Kit (Invitrogen, 18080-400) in the presence of Oligo dT. qPCR and quantitation were performed in the Bio-Rad iCycler IQ™ Multicolor Real-Time PCR Detection System using 25 μl IQ™ SYBR® Green Supermix (Bio-Rad, 170-8882), 250 nM of each primer and 1 μl of cDNA. Each sample was run in triplicate. The amplification ramp included initial hold of 5 min at 94°C, followed by a three step cycle consisting of denaturation at 94°C (30 s), annealing at 57°C (30 s) and extension at 72°C (30 s) and the amplification fluorescence was read at the end of the cycle. The quantitative expression value for each specific transcript was normalized to that of the GAPDH. Ratios of Fgf8 and Fgf10 transcripts at each time point relative to that at E14.5 are shown from E11.5 to P5.
Isolation of lung mesenchymal and epithelial cells E15.5 embryonic lungs were isolated and the tissue minced in ice cold PBS. A single cell suspension was obtained by 0.5% collagenase (Sigma, C0130) digestion at 37°C for 45 min and then incubated with RBC lysis buffer (Sigma, R7757) at RT for 15 min to remove red blood cells. The cells were filtered through a 100-μm cell strainer and resuspended in DMEM with 10% fetal calf serum. Mesenchymal cells and epithelial cells were isolated based on their differential adherence to culture flask plastic over time. Adherent cells after the first 45 min in culture were mesenchymal cells; the unattached cells at this 45 minute point were isolated and cultured for an additional 1 h yielding a second batch of attached cells which is a mixture of epithelial cells and fibroblasts; these were discarded. The persistently unattached cells are epithelial cells, which were then centrifuged at low speed (120 g × 3 min) for isolation. Isolated epithelial and mesenchymal cells were fixed in 4% PFA for 20 min on ice and processed immediately. 10 5 cells in 250 μl PBS buffer were added to a cytospin chamber and the specimens were cytocentrifuged at 750 rpm for 3 min, leaving a button of concentrated cells on the slide. For qRT-PCR assay of these isolated populations, cell total RNA sample was prepared using RNAeasy micro Kit (Qiagen, 74004) with the protocol provided by the manufacturer. cDNA synthesis and quantitative PCR procedures were the same as described above.
FGF8 stimulation of lung mesenchymal and epithelial cells and analysis of BrdU incorporation E15.5 mesenchymal and epithelial cells were isolated as above and 4 × 10 5 (epithelial or mesenchymal) cells were plated per well containing a sterilized 12 mm round coverslip in a 24 well plate. Each experimental treatment was repeated in triplicate. Cells were allowed to attach either in the presence or in the absence of serum, with the simultaneous addition of 20 ng/ml FGF8 with 100 ng/ml heparin, or heparin alone. The cells were incubated for 24 or 48 h and BrdU was added to a final concentration of 10 μM, cells incubated an additional 12 h and then rinsed in 1× PBS and fixed in −20°C 100% methanol for 30 min. Coverslips were removed from the wells, washed in PBS, immersed in 2 N HCL for 20 min at room temperature, washed in 0.1 M sodium borate (pH 8.5) for 2 min at room temperature. After washing for 5 min in PBS, they were washed 3 times in a blocking solution containing PBS + 0.2% Triton X100 + 3% BSA for 10 min each and then incubated with BrdU primary antibody (Abcam, ab6326) in block for 2 h. Antibody was removed by 3 × 10 minute washes in block and then Alexa 594 goat anti-mouse secondary was added for I h at room temperature. After final washing in block ×3, the coverslips were mounted in Vectashield with DAPI. 3 randomly selected 200× fields were counted on each coverslip (3 coverslips per experimental treatment, 9 random fields counted in total per experimental treatment group): the total nuclei in living cells per field were counted, as was the subset with BrdU + nuclei. The percent positive nuclei are expressed as (BrdU nuclei/total nuclei) × 100. Quantitation of overall cell adherence, growth and survival (Figs. 5C, D) was performed based on initial plating of 4 × 10 5 cells and each random 200× field counted represents 1/67th of the total surface area of the 12 mm coverslip.
Immunofluorescence
For isolated mesenchymal and epithelial cells, the cells were permeabilized with 0.1% Triton X100 in PBS for 15 min and then blocked with 5% bovine serum in PBS containing 0.1% Triton X100. For sectioned lung, the lung was removed and fixed routinely, embedded in OCT, and sectioned at 10 μm. Immunohistochemical analysis was performed using the following antibodies: anti-FoxA2 (1:1000; Abcam, ab40874), anti-PECAM (1:200; BD Pharmingen, 550274), anti-Nkx2.1 (1:100, GeneTex, 8G7G3/1), anti-SMA (1:100, Sigma, A2547), anti-Aquaporin-5 (1:100; CalBiochem, 178615), and anti-SPC (1:200; Upstate 07-647). Trypsin antigen retrieval was used to unmask the antigen for PECAM detection. Blocking was performed using 5% of goat or donkey serum in PBST. Antibodies were incubated O/N at 4°C. Secondary antibodies conjugated with Alexa 488, Alexa 594 or Cy3 (1:1000; Molecular Probes) were incubated for 1 h at RT. Slides were mounted using VECTASHIELD mounting medium with DAPI (Vector Laboratories, H-1200). Images were obtained using a Zeiss Axio microscope and Zeiss AxioVision software. The anti-SPC signal was imaged on an IX81 Olympus microscope and images captured with a Hamamatsu Orca digital camera with a DSU spinning confocal unit using Slidebook software.
BrdU immunohistochemical staining of mouse lung sections
Mice received intraperitoneal injection of 50 mg/g body weight 5bromo-2′-deoxyuridine (Invitrogen, 00-0103) 2 h prior to sacrifice. The lung was removed and processed routinely, embedded in OCT Compound, and sectioned at 10 μm. Microwave antigen retrieval was performed for 20 min in Antigen Unmasking Solution (Vector Laboratories, H-3300). Endogenous peroxidases were quenched by incubation at room temperature in 1% H 2 O 2 for 20 min followed by rinsing in PBST (PBS with 0.1% Tween 20). Blocking was performed using 5% donkey serum in PBST. Rat anti-BrdU primary antibody (Abcam, ab6326) in 5% donkey serum was added to the tissue sections at a 1:1000 dilution. Sections were incubated overnight at 4°C and then rinsed in PBST. Biotinylated specific staining was detected with biotinylated donkey anti-rat secondary antibody (Jackson ImmunoResearch, 712-065-153) horseradish peroxidase complexes using VECTASTAIN Elite ABC kits (Vector Laboratories, PK-6100). Antigenantibody complexes were visualized using DAB Substrate (Vector Laboratories, SK-4105). The labeling index was expressed as the number of BrdU-positive ratio and counted by Image-Pro Plus v. 6.0software (Media Cybernetics, Inc). Results were expressed as means ± SE of at least 3 mice per group and p values were calculated using Student's two tailed t-test.
β-Galactosidase staining
MesP1 and Islet1 lineage analysis was performed with a standard breeding strategy in which the females contained the conditional Rosa26 lacz reporter allele (Soriano, 1999) and the males carried the MesP1Cre or Islet1Cre alleles. E11.5 embryos were stained for βgalactosidase activity using a standard protocol. All embryos from a litter were fixed in 0.2% glutaraldehyde in PBS, 0.02% NP40 (PBN) on ice for 15 min, washed in PBN, and placed in X-gal staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM Fig. 1 . Fgf8 hypomorphic mutants die at birth with dysplastic, hypercellular lungs. A-D) Whole mount E18.5 control (Fgf8 H/+ ) and hypomorph (Fgf8 H/− ) littermate mice (A, B) and lungs (C, D) photographed side-by-side; note that in spite of the overall decrease in body size of the mutant, the lungs are as large as those in controls (vertical black lines in C and D are the same size). E-F′) Low (E, F) and high (E′, F′) magnification photographs of H&E stained paraffin sections from P0.5 inflation-fixed lung preparations. Note the hypercellular, thickened septal walls (compare red arrows in E′ and F′) and location of many red blood cells (pink stained cells, located in capillaries) embedded in the septa whereas in the control the red blood cells are immediately adjacent to the airspaces. TRU; terminal respiratory unit.
MgCl 2 , and 1 mg/ml X-gal, in PBS, pH 7.3). Staining was carried out overnight at room temperature while rocking. After staining, embryos were washed in PBN and post-fixed in 4% paraformaldehyde overnight at 4°C. Embryos were then rinsed in PBS and cleared in glycerol for photographs, embedded in paraffin, sectioned transversely, and counterstained with nuclear Fast Red.
Results
Decreased Fgf8 function disrupts lung development
Fgf8 expression is required in multiple temporospatial expression domains during vertebrate development, and null embryos die early in embryogenesis (Meyers et al., 1998; Moon and Capecchi, 2000; Sun et al., 1999) . The phenotypes of Fgf8 hypomorphs (produce less than 50% of the normal amount of Fgf8 mRNA) revealed the essential functions of this protein in cardiovascular, nervous system, limb and pharyngeal development and left-right patterning (Abu-Issa et al., 2002; Frank et al., 2002; Meyers et al., 1998; Moon, 2006) . Subsequent conditional mutagenesis experiments have been instrumental in further dissecting the requirements for Fgf8 activity at different times and locations (Ilagan et al., 2006; Lewandoski et al., 2000; Macatee et al., 2003; Moon, 2006; Moon and Capecchi, 2000; Park et al., 2006; Trumpp et al., 1999) .
We previously reported that 100% of Fgf8 deficient hypomorphs (Fgf8 H/− , animals bearing a hypomorphic allele and a null allele of Fgf8) die in the first postnatal day with cyanosis; however, only 40% of these mutants have predictably lethal cardiovascular defects (Frank et al., 2002) . We observed these animals after birth and noted that in spite of significant respiratory effort, they uniformly became cyanotic and died within hours of birth. Thus, we questioned whether pulmonary defects contribute to their postnatal death and so collected lungs from Fgf8 H/− hypomorphs, and their wild type, null heterozygote (Fgf8 +/− ) or hypomorph heterozygote (Fgf8 H/+ ) littermates at E18.5 and immediately after birth (P0.5). On gross pathology at E18.5, the lungs of the Fgf8 H/− mutants are much larger relative to total body size than controls (Figs. 1A-D, fetuses are photographed side-by-side; longitudinal black bars superimposed over the lungs are the same length, and the lungs are photographed side-by-side). This correlates with a significantly increased lung to body weight ratio in the mutants (6.9 ± 0.7% in Fgf8 hypomorphs versus 4.9 ± 0.8% in controls, p = 0.04, N = 4) that is not attributable to edema, because mutants also have increased dry to wet lung weight ratio (12.9 ± 1.9% in Fgf8 mutants versus 9.1 ± 0.3% wild type, p = 0.02). Thus the mutant lungs are hyperplastic. In fact, at P0.5 when all controls have generated large air spaces, thin septa (Figs. 1E, E′ control red arrows), and a wellorganized capillary network, the mutants have dramatically hypercellular septa that appear not to have progressed beyond the early saccular stage; the capillary network (as visualized by the bright pink red blood cells in Fig. 1F′ ) is largely remote from the airspaces embedded in thick septal walls (Figs. 1F, F′, mutant red arrows). Thickness of the septal walls in mutants is 150% that of controls (4.9 ± 0.7 μm controls versus 7.6 ± 1.5 μm mutants, p b 0.05, N = 6).
Fgf8 is expressed at low levels in the developing mouse lung Fgf8 mRNA transcripts have previously been detected in E12.5 mouse and adult rat lung (Lin et al., 2002; Schmitt et al., 1996) ; however the expression of Fgf8 at other stages has not been characterized. We assayed Fgf8 transcripts in whole lung lobes from wild type mice (all proximal airways and vessels were removed) by quantitative RT-PCR; Fig. 2A shows the expression level at each stage relative to the level at E14.5 (data shown are normalized to gapdh). We detected expression at all stages of prenatal lung development, with a marked increase at postnatal day 5 (P5). Normalization to βactin also revealed a marked increase in the relative level of Fgf8 expression postnatally (not shown). No Fgf8 transcripts were detected in RNA prepared from Fgf8 null embryo negative controls. The absolute cycle threshold (Ct) values for Fgf8 in the lung ranged from 29 to 33, indicating a low number of transcripts and consistent with our inability to detect the mRNA signal above background by in situ hybridization with digoxigenin-or 35 S-labeled antisense riboprobes (not shown). In contrast, Fgf10 transcripts were detected with absolute Ct values ranging from 15 to 19 ( Fig. 2B ) and levels increased steadily over the course of prenatal lung development, as has been reported (Bellusci et al., 1997) .
To determine whether Fgf8 is expressed in both the mesenchymal and epithelial cellular compartments of the developing lung, we dissociated E15.5 lung tissue and isolated epithelial from mesenchymal cells using a protocol adapted from Schuger et al. (1993) , based on the differential adherence of dissociated cells types over time to standard tissue culture flasks. This method provides excellent separation of epithelial and mesenchymal cells as demonstrated by analysis of cytospin preparations of the two populations with mesenchymal (PECAM, SMA; Figs. 3A, A′, B, B′) and epithelial (Nkx2.1, FoxA2; C, C′, D, D′) protein markers. When we assayed these isolated populations for transcript levels using qRT-PCR, and compared the ratio of transcripts detected in the mesenchymal versus epithelial compartments, we found that Fgf8 transcripts are relatively enriched epithelial cells (6.5 fold), along with transcripts for Foxa2 and Shh, while Pecam and Fgf10 transcripts were enriched in mesenchymal cells, as expected ( Fig. 3E ). The source of Fgf8 transcripts in lung is not red blood cells or another circulating cell type, as these experiments were performed after red blood cell lysis, and we have specifically found that Fgf8 transcripts are undetectable in E15.5-17.5 fetal blood (data not shown).
All four Fgf receptors are expressed in the lung (Powell et al., 1998 ) and we quantitated the relative levels of FGF receptor transcripts in these isolated cell populations (Supplemental Table 1 ). We obtained the expected ratios for FgfR2b and FgfR2c (enriched in epithelia and mesenchyme, respectively (Arman et al., 1999) ) and detected expression of FgfR1b and c, FgfR3, and FgfR4. While these data are not absolute transcript numbers, we have optimized efficiency of all primer sets and thus the dCt values (Ct of the gene of interest less that of the housekeeping gene) can be compared for relative abundance of the different FgfR amplicons. These data indicate that FgfR1 isoform b and c transcripts are present at comparable levels to that of FgfR2 b and c in the epithelium and mesenchyme, respectively. We were unable to generate reliable isoform specific primers for FgfR3; our data confirm that FgfR3 and FgfR4 transcripts are expressed in both the epithelial and mesenchymal compartments.
Fgf8 deficiency causes excess proliferation and disrupts the fetal phase of lung development
Given the markedly thickened septal walls observed in the hypomorphs, we tested whether excess proliferation was a contributing mechanism. We labeled S-phase cells with an intraperitoneal pulse of BrdU administered to the mother 2 h prior to fetal harvest and performed anti-BrdU immunohistochemistry at multiple stages of lung development. While the percentage of labeled cells was not different between hypomorphs and controls at the late embryonic and early fetal stages (E13.5-15.5; Figs. 4A-C), by E16.5, proliferation in the mutants both visually and statistically exceeded that in controls by more than 2 fold in both the distal epithelium and mesenchyme (Figs. 4A, B, C). Furthermore, although the total percentage of proliferating epithelial and mesenchymal cells decreases in the hypomorphs at E17.5 and E18.5 (as it does in controls), it remains abnormally high (Figs. 4A, D). We assayed for apoptosis using the TUNEL assay in these specimens and found only rare TUNEL+ cells in both mutants and controls (data not shown).
FGFs generally stimulate cell proliferation and FGF9, 10 and 18 all do so in the lung in vivo (Bellusci et al., 1997; Colvin et al., 2001; Usui et al., 2004) . Although the cell proliferation and survival responses to FGF8 are dosage and context dependent (Storm et al., 2003 (Storm et al., , 2006 , the hyperproliferative lung phenotype in FGF8 deficient mutants is nonetheless surprising. To better understand whether excess proliferation of both mesenchymal and epithelial cels in the mutants represents a direct or secondary consequence of FGF8 deficiency, we assayed whether FGF8 stimulates or represses proliferation of lung epithelial and mesenchymal cells at E15.5. Isolated cells were cultured for 24 and 48 h in the presence or absence of serum and recombinant FGF8b and then pulsed with BrdU and immunostained.
As shown in Fig. 5A , by 24 h FGF8 had significantly increased the percentage of BrdU-positive mesenchymal cells both in the absence (columns a and b, 2.3 fold increase, p b 0.001) and presence (columns c and d, 1.2 fold increase, p b 0.001) of serum, and at 48 h in the absence of serum (columns e and f, 2.7 fold, p b 0.001). The cumulative effects of adherence to substrate, survival and growth of the cultured mesenchymal cells on total cell number at the time of counting are shown in Fig. 5C . At 24 and 48 h in the absence of serum, approximately 120% of the number of mesenchymal cells initially plated were present (compare columns a and e) and this was not significantly affected by FGF8 (columns b and f); the negligible increase in mesenchymal cell number at 48 h in the serum-free groups is likely attributable to their already being nearly confluent at 24 h. Significantly fewer mesenchymal cells were present at 24 h in the serum-treated groups (columns a versus c, 1.4 fold decrease, p b 0.0001; columns b versus d, 1.2 fold decrease, p = 0.02); the reason for this effect is unclear, but may be due to decreased attachment to the culture substrate. The lower cell number/lower confluence at 24 h in the serum-treated cells appears to have permitted cell proliferation over the next 24 h, as evident by the significantly increased number of cells present at 48 h(columns c versus g, 1.5 fold increase, p b 0.0001; columns d versus h, 1.5 fold increase p b 0.0001).
The results obtained with cultured lung epithelial cells were dramatically different. First, the number of cells surviving as a percent of the number plated was much lower than for mesenchymal cells in all groups (Fig. 5D ). Unlike mesenchymal cells, the epithelial cells were dependent on serum for adherence, growth and survival because at 24 h in the absence of serum, there were fewer epithelial cells per well than in serum-treated wells (Fig. 5D , columns a versus c, 5.2 fold increase with serum, p b 0.0001; columns b versus d, 3.8 fold increase, p b 0.001; columns f versus h, 2.7 fold increase p b 0.001). The serumfree cells did not increase BrdU incorporation in response to FGF8 (Fig. 5B, columns a and b ). Most remarkably, in the presence of serum, FGF8 treatment decreased the percentage of proliferating epithelial cells at 24 (Fig. 5B , columns c versus d, 1.4 fold decrease, p b 0.001) and 48 h (Fig. 5B , columns g versus h, 1.5 fold decrease, p b 0.001). After 48 h, the majority of epithelial cells cultured in the absence of serum had pyknotic nuclei, but we scored those with normal nuclear morphology and none had incorporated BrdU either in the presence or absence of FGF8 (Fig. 5B , columns e and f). Although the presence of serum permitted better survival of epithelial cells to 48 h (Fig. 5D , columns f versus h), FGF8 nonetheless decreased BrdU incorporation in these cells (Fig. 5B, columns g and h) . In total, these data indicate that FGF8 at the dosage employed here has opposite effects on BrdU incorporation in epithelial versus mesenchymal cell types.
In order to obtain a picture of the molecular pathways that were dysregulated in association with the excess proliferation seen in the fetal mutant lung, we performed a genome-wide expression analysis comparing E18.5 Fgf8 hypomorphic lungs to wild type controls. The direction and magnitude of the changes were very consistent between the 4 arrays, conferring high statistical power to our analysis. Furthermore, we analyzed expression of 46 genes of interest by qRT-PCR and in 43, the findings validated those of the microarray, a specificity of 93% (Supplemental Table 2 ). Microarrays are less sensitive than qRT-PCR and in this experiment the fold change reported by the microarray usually underestimated the magnitude of the changes in transcript levels (or did not detect differences) detected by qRT-PCR. In addition to examining absolute fold-changes, we used pathway-based analysis in order to detect modest, yet potentially functionally relevant changes in the context of multiple "hits" to a pathway (Curtis et al., 2005; Park et al., 2008) . KEGG analysis revealed that the most overrepresented category of dysregulated genes was "Cell cycle" (60 upregulated, z-score 10.66, heat map not shown due to large number of genes); the changes were overwhelmingly in the direction of excess proliferation, consistent with our BrdU results. Overrepresented downregulated genes in the "Focal adhesion" pathway (53, z = 7.03) and "ECM-receptor interaction" pathway (31, z = 7.43) suggest that disrupted contact inhibition may contribute to the hyperproliferative state. Wnt ligands, receptors and canonical target gene transcripts were increased, while those of numerous Wnt inhibitors were decreased ( Fig. 6 ). Of the FGF ligands expressed in lung, Fgf8 (the level of transcripts in mutant lung assayed by qRT-PCR was 7.8 fold lower than in controls), Fgf10 (2.3 fold increased) and Fgf9 (5.7 fold increased) were dysregulated. Expression of FgfR3 and FgfR4 was decreased, while that of FgfRs 1 and 2 were unchanged ( Supplementary Table 2 ). Other findings relevant to lung morphogenesis and the Fgf8 mutant fetal/postnatal phenotypes are shown in the heat maps in Fig. 6 . Results are expressed as a fold change in mRNA level (up-red, down-green) in mutants versus wild type. Critical mediators of VEGF signaling and vascular maturation were decreased. The profile of many glucocorticoid target genes is similar to that reported in glucocorticoid receptor null mutants, which also have a hyperproliferation phenotype (Bird et al., 2007) . ECM structural, remodeling, and signal modulating genes that are aberrantly expressed include several encoding metalloproteases, ctgf (connective tissue growth factor), igfbp3 (IGF binding protein 3), ibsp (Integrin binding sialoprotein) and loxl2 (lysl oxidase 2). In total, the gene expression changes and other phenotypic features support the hypothesis that decreased FGF8 signaling causes dysfunction of pathways that regulate proliferation, cell-cell and cell-ECM interactions, and differentiation in the distal fetal lung.
The presence of Fgf8 transcripts at multiple developmental stages led us to hypothesize that the pulmonary phenotype in Fgf8 hypomorphs Fgf8 is expressed at low levels throughout prenatal lung development and increases markedly postnatally. Quantitative reverse transcription-PCR was used to assay Fgf8 (A) and Fgf10 (B) transcript levels in lung tissue prepared from E11.5-P5 specimens. Fold expression is shown relative to that at E14.5 and normalized to gapdh. Fgf10 quantitation is shown for comparison and increases gradually over this time period. Ct; cycle threshold value. reflects a specific requirement for FGF8 in the developing lung; however, widespread defects in organogenesis and function, including variable cardiovascular defects in these hypomorphs could theoretically have secondary effects on lung development. Furthermore, the hypomorphic allele contains a neomycin phosphotransferase gene that can adversely affect function of both adjacent and distant genes (Frank et al., 2002; Olson et al., 1996) raising the possibility that the lung phenotype results from dysfunction of a different locus (note that this would predict that the phenotype would be present in hypomorph heterozygotes, which is not the case: Figs. 1A, C, E) . To test our hypothesis and rule out possible confounding effects of other loci, we used a nonhypomorphic conditional allele of Fgf8 (Park et al., 2006) and two Cre drivers with different temporospatial activities to specifically test the effects of Fgf8 loss-of-function on lung development. Isl1Cre is active in pharyngeal endoderm, including pulmonary epithelial precursors, and in a subset of mesoderm from E8.5 (Park et al., 2006) . MesP1Cre activity is strictly restricted to anterior mesoderm (Park et al., 2006; Saga et al., 1999) , including pulmonary mesenchymal precursors. The blue β-galactosidase staining in panels E and F of Fig. 7 indicates regions of Cre-mediated recombination of the ROSA26 lacZ Cre reporter gene (Soriano, 1999) . By E10.5, MesP1Cre has already recombined the reporter throughout the lung mesenchyme (Me, Fig. 7E ) and Isl1Cre has recombined the reporter in the lung epithelia (Ep, Fig. 7F ) but only a subset of the lung mesenchyme. Remarkably, E18.5, Fgf8;Isl1Cre mutants phenocopy the lung defects of Fgf8 hypomorphs (compare Figs. 7C, C′ to D, D′): the mutants survive to birth but die with cyanosis postnatally and their lungs have hypercellular septa and a paucity of capillaries (Figs. 7D, D′, and Fig. 9 ). Fgf8;Isl1Cre mutants exhibit the same excess proliferation from E16.5 seen in hypomorphs (Fig. 8 ). This is in spite of the fact that proliferation in mesenchyme of controls at E14-5-16.5 in this genetic background (Bl Swiss/SV129/C57Bl6) is slightly higher than that seen in the background in which the hypomorphs are maintained (SV129/C57Bl6) as shown in Figs. 4A, B versus 8A, B . In notable contrast to the variable cardiovascular phenotypes of Fgf8 Fig. 3 . Separation of epithelial and mesenchymal cells from E15.5 lungs reveals enrichment of Fgf8 transcripts in the epithelial compartment. Immunocytochemistry using the antibodies/markers listed at top to assay isolated mesenchymal (A-D) and epithelial (A′-D′) lung cells. Note that SMA and PECAM are detected as expected in mesenchymal cells (A and B, respectively) but not in epithelial cells (A′, B′) while Nkx2.1 and FoxA2 label epithelial cells. These staining patterns validate the stringency and specificity of the cell isolation method. E) Quantitative reverse transcription-PCR was used to compare transcript levels in the isolated mesenchymal and epithelial cells; Fgf8 transcripts were 6.5 fold greater in the epithelial cells. Other marker transcripts used as controls were present in the expected cellular compartments.
hypomorphs (Frank et al., 2002) , 100% of Fgf8;Isl1Cre mutants have the cardiac outflow tract defect, persistent truncus arteriosus (Park et al., 2006) . Ablation of Fgf8 only in mesodermal lung precursors using MesP1Cre (Figs. 7B, B′, E) does not recapitulate the mutant phenotype even though we have shown that Fgf8;MesP1Cre mutants also have vascular and outflow tract defects (Park et al., 2006; Watanabe et al., 2009 ). The different lung phenotypes in Fgf8;Isl1Cre versus Fgf8; MesP1Cre mutants indicate that cardiovascular defects are not the cause of the lung phenotype in Fgf8;Isl1Cre or Fgf8 hypomorphs. We have also confirmed the independence of the lung and cardiac outflow tract phenotypes in Fgf8;Hoxa3IresCre mutants (Macatee et al., 2003) ; these mutants have pancellular CRE activity caudal to the second pharyngeal arch from~E8.5 and although they only rarely have outflow tract defects (Macatee et al., 2003) , they also have the lung phenotype (not shown).
These data cumulatively indicate that the pulmonary and cardiovascular phenotypes reflect separate requirements for Fgf8 function in development of the lung versus the heart/great vessels, respectively. The conditional ablation experiments rule out secondary effects or dysfunction of other loci as a cause of pulmonary defects in Fgf8 hypomorphic and Fgf8;Isl1Cre conditional mutants, and support our hypothesis that FGF8 signaling is specifically required for lung development. The different tissue specificities of Isl1Cre and MesP1Cre suggest that Fgf8 function is required in endodermal precursors of lung epithelia or later in their derivatives to support late fetal lung development.
Lung development occurs normally through the embryonic and pseudoglandular stages in Fgf8;Isl1Cre and hypomorphic mutants, but is disrupted in the canalicular stage by excess proliferation, failure of differentiation, and abnormal septal and vascular remodeling
The Fgf8 hypomorphs revealed a great deal about the importance of proper Fgf8 function for normal lung development, but to avoid potential confounding pleiotropic effects on lung development in Fgf8 hypomorphs, and to focus our efforts using a defined loss-of-function mutant with invariant phenotypes, we performed further immunohistochemical exploration of the Fgf8 mutant phenotype in Fgf8; Isl1Cre conditional mutants. All experiments were repeated on a minimum of 3 mutants (from each class) and littermate control lung samples at each stage; control and mutant specimens were processed on the same slide and the results are highly reproducible. There is a dramatic increase in the number of labeled cells in the mesenchyme and epithelia from E16.5 onward (red boxed panels). Note that the morphology of the mutant lung also appears normal prior to E16.5. B) Quantitation of distal mesenchymal proliferation confirms statistically significant increases in number of BrdU-labeled nuclei in mutants at E16.5. **p b 0.005. C) Quantitation of epithelial cell proliferation confirms statistically significant increases in number of BrdU-labeled nuclei in mutants at E16.5. **p b 0.005. D) Fraction of total (mesenchymal + epithelial) BrdU-labeled nuclei is significantly increased in mutants at both E17.5 and E18.5. **p b 0.005. Expansion of air spaces and thinning of primary septa occur in the late fetal period concurrent with vascular remodeling. Efforts to dissect the regulation of late fetal and postnatal alveolar development have been hindered by the fact that lung development in most mouse models of disrupted lung development is already abnormal at embryonic stages. However, at the embryonic and early pseudoglandular stages (E13.5 and E14.5), Fgf8;Isl1Cre and Fgf8 hypomorphic mutant lungs have normal FoxA2, Nkx2.1, PECAM and smooth muscle actin (SMA) immunoreactivity (Supplemental Figs. 1-3) . Lung morphology and proliferation were also normal through the pseudoglandular and early canalicular stages in Fgf8;Isl1Cre and Fgf8 hypomorphic mutants (Figs. 4, 8 and Supplemental Figs. 1-3) .
To better characterize the abnormalities present at the late fetal stages we examined numerous immunohistochemical markers in Fgf8;Isl1Cre mutants ( Fig. 9) and Fgf8 hypomorphs (Fig. 10) compared to littermate controls. At E16.5, production of FoxA2 in the distal airway epithelia and of PECAM in endothelial cells appears compa-rable in Fgf8;Isl1Cre mutants and controls (Figs. 9A, A′) . However, at E17.5, control lungs have progressed to the saccular stage and the number of FoxA2+ cells present in the distal lung is decreasing (Fig. 9B, white arrowheads) as immature Type II cells differentiate into Type I cells. In contrast, the Fgf8;Isl1Cre mutant lung has persistent cuboidal FoxA2+ cells surrounding rare, small airspaces ( Fig. 9B′, yellow arrowheads) . The pattern of PECAM reactivity still appears normal in Fgf8;Isl1Cre mutants at this stage (Figs. 9E, E′) . By E18.5, the control lung has many large airspaces and an adjacent, well-organized capillary network encompassing the thin septa in readiness for gas exchange at birth (Figs. 9C, F ). However, Fgf8;Isl1Cre mutant septa are thickened and hypercellular, and many cuboidal FoxA2+ cells still line the saccules (Fig. 9C′, yellow arrowheads) ; the vessels are intraseptal with decreased PECAM immunoreactivity (Fig. 9F′, yellow arrowheads) . Consistent with the FoxA2 staining pattern, controls at this stage display very few cuboidal, Nkx2.1+ cells (Fig. 9G , blue nuclei, green Nkx2.1, white arrowheads) at the airspace (c, d and g, h) . **p b 0.001, *p b 0.01. C, D) Overall adherence, growth and survival of cultured E15.5 lung cells as reflected by the number of total cells present at the time of assay represented as a percent of the number initially plated. C) Fewer mesenchymal cells are present at 24 h when cultured in the presence of serum regardless of the presence of FGF8 (compare a to c, and b to d) but these cells then proliferate over the next 24 h to increase the total number of cells by 1.5 fold (g, h). D) Few epithelial cells adhere or survive to 24 h in the absence of serum and FGF8 treatment slightly improves viability in the first 24 h in the absence of serum (a versus, b). Serum dramatically improves the number of cells present at 24 h although these numbers are still b 50% of that achieved by mesenchymal cells and FGF8 has no additive effect to serum (c, d). There are significantly fewer cells in the FGF8 treated serum-free group at 48 h (e versus f) and this is remedied by treatment with serum (h) **p b 0.001, *p b 0.01. interface however, many undifferentiated Nkx2.1+ cells line the small airspaces in the mutants. The fraction of total cells that are Nkx2.1+ in wild type lungs at E18.5 was 0.15 ± 0.02, while that in Fgf8;Isl1Cre mutants was 0.29 ± 0.05, p = 0.01. Increased immunoreactivity for surfactant protein C in the mutant epithelia (Fig. 9J ) supports the hypothesis that the excess Nkx2.1/FoxA2+ epithelial population represents Type II alveolar cells that have failed to differentiate into Type I cells. Fgf8 hypomorphs display the same immunohistochemical abnormalities at E18.5 (Fig. 10) .
Abnormalities in the septa, airway epithelium and capillary network are even more severe in Fgf8;Isl1Cre mutants just prior to birth (E19, Figs. 9K-L′). Compared with controls, fewer PECAM+ capillaries are present in Fgf8;Isl1Cre mutant lungs and the network is hypoplastic and aberrantly located within the thickened septa (yellow, Figs. 9L, L′) . The fraction of total cells that are PECAM+ in wild type lungs at E18.5 was 0.39 ± 0.04, while that in Fgf8;Isl1Cre mutants was 0.19 ± 0.01, p b 0.01. Aquaporin 5+ Type I cells are easily detected outlining the normal elongated plasma membrane at the air interface in controls (Fig. 9M , white staining and arrowheads). In Fgf8; Isl1Cre mutants (Fig. 9N) , and Fgf8 hypomorphs (Fig. 10E′) , minimal Aquaporin 5+ signal is present and the rare, faintly staining cells have failed to develop a normal squamous morphology; this is consistent with the failed differentiation of Type II cells. Thus, numerous crucial events that normally occur at the late saccular/early alveolar stages in preparation for gas exchange at birth fail to occur in Fgf8 mutants.
Discussion
The onset and progression of the Fgf8 mutant lung phenotypes during fetal lung development indicates that sufficient FGF8 is produced in Fgf8;Isl1Cre mutants and hypomorphs to achieve a threshold required for the the embryonic and pseudoglandular stages of lung development, or that FGF8 is functionally redundant with other FGFs during these early periods. FGF8 and FGF18 are the most closely related ligands expressed in the lung epithelium, but the reported phenotype of Fgf18 null mutants is quite distinct from that of Fgf8;Isl1Cre and hypomorphic mutants: Fgf18 null mutants have hypoplastic lungs with decreased cell proliferation and preserved epithelial differentiation (Usui et al., 2004) , while Fgf8 mutants have a hyperplastic phenotype with distal epithelial and mesenchymal overproliferation, and disrupted distal epithelial differentiation. Thus FGF8 and FGF18 are not functionally redundant at fetal stages, and the phenotypes of both classes of Fgf8 mutant indicate that no other FGF can compensate for the loss of FGF8 during fetal lung development. Furthermore, expression of FGF10 and FGF9 is increased in FGF8 hypomorphs at E18.5. These ligands stimulate epithelial and mesenchymal proliferation, respectively, in vivo; if increased gene expression also results in increased protein levels, these ligands may be contributing to the excess proliferation observed in mutants.
The accepted paradigm is that FGFs signal in a paracrine fashion to effect epithelial-mesenchymal communication in the developing embryo. Specific ligand/receptor and receptor isoform binding preferences demonstrated by in vitro binding and mitogenic assays support this idea (Zhang et al., 2006) , and the results of these studies are frequently extrapolated to infer what the functionally relevant interactions are in vivo. However, overlapping receptor binding capacities and expression patterns as well as gene ablation studies in mice clearly indicate that functional redundancy and "unfavorable" ligand/receptor interactions not only occur, but have required functions in vivo (Park et al., 2008; Powers et al., 2000) . For example, no FGF8 isoforms bound or activated the "epithelial" splice forms of FGFR1-3 in vitro (MacArthur et al., 1995) yet studies by us and others clearly indicate that FGF8 does signal to some epithelia via FGFR1 in autocrine loops (Deng et al., 1994; Park et al., 2008; and Moon, unpublished) . Published in vitro data indicate that FGFR3c mediates the greatest response to FGF8, but FGF8 also activated FGFR1 and 2 "c" isoforms and FGFR4 in these mitogenic assays (Zhang et al., 2006) . Work from our lab and many others in vivo suggest that FGFR1 and 2 are crucial mediators of FGF8 signaling in different regions of the developing embryo; this ligand seems to interact with different receptors in a highly context dependent manner and the ultimate cellular effects are context and dosage sensitive (Frank et al., 2002; Meyers et al., 1998; Storm et al., 2003 Storm et al., , 2006 . The ability of a given FGF ligand to bind a particular cell in vivo, and the subsequent effects on the cell are determined by selective ligand/receptor binding and extracellular matrix (ECM) composition, particularly heparan-sulfate proteoglycans because these molecules are functional co-receptors for FGFs. Thus it is not possible to predict a priori what receptor(s) or isoforms are functional receptors for FGF8 in the lung. Temporospatially regulated ablation of candidate receptors will be required to address this question.
Because expression of a soluble dominant-negative form of FgfR2, isoform 2b (the epithelially-expressed isoform) did not disrupt postnatal lung development, it has been argued that alveolar Fig. 6 . Pathway-based heat maps of gene expression changes in E18.5 hypomorphic lung tissue relative to controls. Green symbolizes decreased expression in mutant and red, increased. The four columns in each heat map represent the results from each of the four different experiments and show that the expression changes detected were highly reproducible from array to array. The glucocorticoid map shows genes that have been previously shown to be dysregulated in glucocorticoid receptor null mutant lungs (Bird et al., 2007) . ECM, extracellular matrix; CAM, cell adhesion molecule. Fig. 7 . Loss of Fgf8 function in the epithelia of Fgf8;Isl1Cre conditional mutants phenocopies the lung phenotypes of Fgf8 hypomorphs but ablation in the lung mesenchyme of Fgf8;MesP1Cre mutants does not. A-D′) H&E stained paraffin sections from E18.5 lung specimens obtained from mutants with the genotypes listed at top. Low and high magnification views are shown and were obtained at similar peripheral locations in the lung. B, B′) Ablation of Fgf8 only in the mesenchyme with MesP1Cre permits normal lung development through fetal development. C, C′) Fgf8 hypomorphic mutant lung phenotype. D, D′) Fgf8;Isl1Cre conditional mutant lung has thickened septa and few airspaces, phenocopying the hypomorphic lung. E) The ROSA26 lacz Cre reporter shows that MesP1Cre is active and recombines in all lung mesenchymal (Me) precursors by E11.5 but no evidence of recombination is detectable in the lung epithelia (Ep). F) The ROSA26 lacz Cre reporter shows that Isl1Cre is active and recombines broadly in lung epithelial precursors by E11.5, but only in a subset of lung mesenchyme. development is FGF-independent (Hokuto et al., 2003) . However, this engineered receptor does not block interactions of all ligands that may interact with FGFR2b, nor with FGFR2c or other FGF receptors (Celli et al., 1998) . Importantly, deletion of both FgfR3/FgfR4 permits normal prenatal lung development but disrupts postnatal alveolar formation (Weinstein et al., 1998) . More recently, additional evidence indicates that FGFR3 and 4 play important roles in regulating ECM production, secondary septation, and other aspects of both normal and pathogenic alveolar development, such as seen in infants with bronchopulmonary dysplasia (Boucherat et al., 2007; Park et al., 2007; Srisuma et al., 2010) . It is unknown if FGFR1 or 2 have roles in fetal lung development, but antagonism of FGFR1 function in postnatal rats disrupts alveologenesis (Yi et al., 2006) . We are performing postnatal ablation of Fgf8 to determine if this ligand contributes to postnatal alveologenesis or and if postnatal ablation phenocopies abnormalities seen in FgfR3/4 deficient mice. The potential roles of FGFR1 and 2 in alveologenesis also merit further investigation.
The level of Fgf8 transcripts detected in lung epithelial cells suggests that either the entire epithelium expresses at very low levels, or that only a subset of epithelial cells express Fgf8. Furthermore, the increased level of mesenchymal proliferation in hypomorphs relative to Fgf8;Isl1Cre mutants (in which only a subset of mesenchymal cells have Cre activity, see Figs. 4 and 8) suggests that there may be additive Fgf8 functions in lung epithelia and mesenchyme or that the higher baseline proliferation in the genetic background of the Isl1Cre mutants obscures some aspects of the phenotype. Since ablation of Fgf8 restricted to the mesodermal precursors of the lung using MesP1Cre does not recapitulate the pulmonary phenotype seen in hypomorphs or Fgf8;IslCre mutants, it is likely that Fgf8 function is required in either the endodermal precursors of the lung epithelia or, at later stages in the lung epithelia derived from this endoderm. If Fgf8 function is required in the epithelial precursors, our data suggest that the affected cells are not "symptomatic" during the embryonic or pseudoglandular stages. We are currently investigating the location and fate of Fgf8expressing cells in the developing lung using an Fgf8-lineage tracer gene-targeted line. We hypothesize that excess proliferation due to loss of autocrine FGF8 signaling causes failure of epithelial differentiation and secondary abnormal mesenchymal and endothelial cell Fig. 8 . Excess proliferation occurs in the lungs of Fgf8;Isl1Cre conditional mutants after E15.5. A) Immunohistochemical detection of BrdU-labeled nuclei (brown DAB staining) in lung sections at the ages noted at top (E14.5-18.5). Control specimens are shown in the top row and Fgf8;Isl1Cre conditional mutant specimens in the bottom row. There is an excess in the number of labeled cells in the mesenchyme and epithelia from E16.5 onward (red boxed sections). Note that morphology of the mutant lung also appears normal prior to E16.5. B) Quantitation of distal epithelial proliferation confirms statistically significant increases in number of BrdU-labeled nuclei in mutants at E16.5. Note that proliferation of both cell types is increased in the controls in this background as compared to that of the controls in Fig. 4 . *p b 0.05. C) Quantitation of mesenchymal cell proliferation confirms statistically significant increases in number of BrdU-labeled nuclei in mutants at E16.5. **p b 0.005. D) Fraction of total (mesenchymal + epithelial) BrdU-labeled nuclei is significantly increased in mutants at both E17.5 and E18.5. **p b 0.005. behavior, initiating a cycle that progressively impairs ongoing epithelial/mesenchymal differentiation and vascular remodeling.
That FGF8 protein has important functions in tissues in which its transcript levels are low and difficult to detect by standard methods is not unprecedented; for example, loss of Fgf8 function in the E8.5 pharyngeal mesoderm containing the second heart field, where its expression is very difficult to detect by RNA in situ hybridization, disrupts outflow tract and pharyngeal vascular development (Park et al., 2006; Ilagan et al., 2006; Watanabe et al., 2009) . Unfortunately, available antibodies are also insufficiently sensitive for detection of FGF8 protein in low-level producing tissues and thus were not useful for our attempts to localize FGF8 producing cells in the lung (Moon, unpublished; Sun et al., 2002) .
Our finding of markedly increased proliferation as the first detectable histologic abnormality in Fgf8 mutants suggests that some targets of the transcriptional effectors of FGF8 in the lung reside high in the regulatory hierarchy controlling proliferation. The results in Fig. 5 suggest that FGF8 produced by the epithelium may have different autocrine (anti-proliferative) and paracrine (pro-proliferative) effects in vivo. Our data suggest that excess mesenchymal Fig. 9 . Differentiation and vascular remodeling are disrupted at the saccular and early alveolar stages in Fgf8;Isl1Cre conditional mutants. All panels show immunohistochemical stains of cryosectioned lung specimens at the ages stated. A-C′) Staining for FoxA2 protein in the distal epithelia (red) from E16.5 to E18.5. There are few FoxA2+ cells lining the forming airspaces in E17.5 and E18.5 controls (B, C white arrowheads) and a normal pattern in mutants at E16.5 (A′). At E17.5 (B′) and 18.5 (C′) mutants have a paucity of airspaces and persistent high numbers of FoxA2+ cells (yellow arrowheads) in the developing airspaces. D-F′) Staining of the developing pulmonary vasculature for PECAM immunoreactivity (green) reveals grossly normal vascular development in the mutants until E18.5; at E18.5 there is less detectable staining (F′, yellow arrowheads). G-H)Consistent with the FoxA2 data, double staining for Nkx2.1 (green) and nuclei (blue) shows a few Nkx2.1+ cells located in the septa, but not lining the airspaces of controls (white arrowheads) while there is abnormal persistence of many Nkx2.1+ cells lining the small airspaces of the mutants (red arrowheads). I, J) Double staining for surfactant protein C (SPC, red) and nuclei (blue) shows increased number of SPC+ Type II alveolar cells or a more primitive precursor cell lining the airspaces. K-N) Analysis at E19. Double staining for PECAM (yellow/green) and nuclei (red) reveals that, relative to controls (K, K′), there is a paucity of distal vessels and vessels are aberrantly located with the thickened septa of the mutants (L, L′) rather than adjacent to the airspaces. Aquaporin 5 staining reveals paucity of Type I cells lining the airspaces and their aberrant cuboidal morphology in mutants (N, arrowheads) as compared to their larger surface area and squamous morphology which gives a fine reticular pattern in controls (M, arrowheads).
proliferation seen in the mutants may not be a primary result of FGF8 deficiency and that FGF8 does not directly repress proliferation in these cells but rather, regulates downstream pathways such that the excess proliferation is a secondary event. An important caveat to this hypothesis is that in vivo, cellular responses such as proliferation, differentiation or cell death in different developmental contexts are very sensitive to the dosage of FGF8 sensitive (Frank et al., 2002; Meyers et al., 1998; Storm et al., 2003 Storm et al., , 2006 ). An outstanding question is whether the different effects we observed on BrdU incorporation, adherence, growth and survival in cultured cells are the result of differential receptor activation in mesenchymal versus epithelial cells (Supplemental Table 1 ), or attributable to relative dosage effects: very few epithelial cells attach and survive over the initial culture period and thus the remaining cells may be exposed to a higher ongoing effective dose of FGF8 than in the mesenchymal cultures. Clarifying the in vivo effects of FGF8 on proliferation of these different cells types will require precise temporospatial gene ablation and inducible transgenic rescue experiments.
The E18.5 transcriptional profile (Fig. 6) represents an advanced stage of the Fgf8 mutant phenotype and thus does not reveal the most proximal molecular defects downstream of loss of FGF8. The alterations in Wnt pathway gene expression are particularly provocative because the profile suggests canonical pathway activation (including upregulation of Wnt7b (Rajagopal et al., 2008) ) which would stimulate proliferation (as would the increases in Shh, Bmp and FGF activity suggested by the microarray and qPCR expression data, Fig. 6 and Supplemental Table 2 ). However, the profile with regard to Wnt signaling is complicated by increased levels of Wnt5a transcripts; this ligand has been shown to decrease proliferation in lung and overexpression stimulated Fgf10 in transgenic mice (Li et al., 2002 (Li et al., , 2005 Tai et al., 2009 ). It will be necessary to determine which pathways are primarily disrupted at the onset of the phenotype to identify those that "trigger" the phenotype and whether the mesenchyme or epithelium is the primary FGF8 target. Expression analyses of isolated mesenchymal and epithelial cell populations isolated from earlier stage wild type and mutant lungs are needed to identify these most proximal molecular events.
The fact that many regulators of ECM composition are dysregulated may provide important insight into the origin and/or progression of the phenotype. ECM constitution modulates bioavailability and signal transduction of numerous growth factors and morphogens. Several regulatory targets of the Ets transcription factors Pea3 and Erm that are regulated by, and mediate transcriptional effects of FGF8 are ECM remodeling enzymes (Brent and Tabin, 2004; Firnberg and Neubuser, 2002; Moon et al., 2006; Park et al., 2006; Raible and Brand, 2001; Roehl and Nusslein-Volhard, 2001; Crawford et al., 2001; Crawford and Matrisian, 1996) . Both of these Ets factors are widely expressed in the lung, and expression of a dominant negative Erm/Engrailed fusion protein in airway epithelia resulted in excess Type II and absence of Type I cells (Liu et al., 2003) , remarkably similar to what we observe in Fgf8 mutants. Interrogation of earlier molecular abnormalities in Fgf8 mutants may reveal that the proximal event that stimulates excess proliferation and ultimately disrupts numerous signaling cascades is altered ECM composition and intercellular interactions. For example, CTGF modulates signaling of diverse pathways via effects on the ECM. IBSP is regulated by Tgfβ and interacts with both matrix metalloproteinases and integrins to influence cell adhesion, epithelial-mesenchymal interactions and ECM deposition. Loxl2 is a lysyl oxidase that catalyzes crosslinking of elastin and collagens, and influences cell adhesion and mobility (Peinado et al., 2008) .
The IGF pathway regulates proliferation in fetal and postnatal lung and is normally downregulated as the distal epithelia matures (Batchelor et al., 1995; Schuller et al., 1995; Boucherat et al., 2007) . IGF ligands, binding proteins (IGFBP) and their receptors are widely expressed in fetal lung, but it is IGFBPs that are most dynamically regulated with stage. IGFBP3 inhibits proliferation and causes apoptosis in some cell lines independently of IGF receptor function and decreases cell proliferation in the lung (Jones and Clemmons, 1995) and its expression is markedly decreased in the hyperproliferative lungs of Fgf8 mutants.
Another potentially important link between abnormal expression of Igfbp3 and Loxl2, increased cell density, and the progressively dysplastic capillary network in Fgf8 mutant lungs is raised by a recent report that these genes are regulated by elements containing Ets binding motifs adjacent to hypoxia-response elements (Aprelikova et al., 2006; Salnikow et al., 2008) . This suggests that progression of some aspects of the Fgf8 mutant phenotype may be driven by metabolic demand of the hyperplastic mutant lung exceeding its blood supply.
Mice born after deficient fetal glucocorticoid signaling die from respiratory failure; their distal airspaces are abnormally remodeled and have not progressed past the canalicular stage. They have reduced numbers of Type I, but not Type II cells, and reductions in surfactant protein production (Cole et al., 1995 (Cole et al., , 2004 Muglia et al., 1995) . Recent studies have shown that a major defect in glucocorticoid receptor null mutants is an excess of proliferating cells in both the mesenchymal and epithelial compartments of the distal lung at E18.5 (Bird et al., 2007) . Although CNS malformations in Fgf8 mutants could affect function of the hypothalamic/pituitary/adrenal axis and fetal glucocorticoid production, it has been established that lung maturation does not depend on fetally synthesized glucocorticoids, but rather on those produced by the mother (Muglia et al., 1995 (Muglia et al., , 1999 .
Relatively little is known about the factors that direct pulmonary vascular development and coordinate it with that of the airways (Perl et al., 2002; Roman et al., 1998; Warburton et al., 2000) . Our observation of progressive loss of PECAM staining and an attenuated vascular network in Fgf8 mutants will provide an important model in which to study these molecular and cellular events. Bidirectional epithelial mesenchymal signaling between respiratory epithelium and endothelial cells is required for differentiation and maturation of both populations (Bhatt et al., 2000) . Loss of even a single copy of Vegfa results in early embryonic lethality due to widespread defects in vasculogenesis and angiogenesis (Carmeliet et al., 1996) . Endothelial cell proliferation reflects the relative expression levels of the Vegf receptors Kdr and Flt-1 throughout the stages of lung development and vascular reorganization; these receptors mediate opposing responses that are critical for both vascular and airway morphogenesis (Galambos et al., 2002) . Kdr expression depends on VEGF signaling and loss of VEGF and the resultant decrease in Kdr expression disrupts endothelial and primary saccular septal development (Yamamoto et al., 2007) , as well as postnatal alveolar formation. Endothelial PECAM function is also required for airway development independent of its effects on endothelial cell proliferation and survival (DeLisser et al., 2006) . Thus the decrease in Vegfa transcripts seen on the microarray (and confirmed by qRT-PCR) combined with decreased expression of Flt1, Kdr and Pecam is likely highly significant for both the vascular and epithelial aspects of the Fgf8 mutant phenotype.
Fgf8 mutants have fewer Type I cells and aberrant persistence of Nkx2.1/SPC positive pneumocytes lining the distal airways. Nkx2.1 (also called Thyroid transcription factor-1) encodes an Nkx family member that activates expression of several lung-specific genes and is required for normal airway branching and epithelial development (Kimura et al., 1996) . Persistent Nkx2.1 expression in the distal lung epithelia causes Type II cell hyperplasia and inhibits alveolarization , similar to what we observe in Fgf8 mutants. This supports our hypothesis that FGF8 signaling is essential for the function of specific pathways that regulate differentiation and progression from the saccular to the alveolar stage.
Conclusion
Our studies reveal that Fgf8 function is required to correctly regulate proliferation and support remodeling and differentiation during the saccular to alveolar transition. The relatively high level of Fgf8 expression in postnatal lung (Fig. 2, P1 and P5) suggests that this factor may also play a role in alveologenesis. Our future experiments will employ temporspatial-specific conditional loss-of-function to define the window of Fgf8 activity required for the saccular to alveolar transition and test whether this factor is also required for postnatal lung morphogenesis.
Therapies for alveolar dysplasia, associated surfactant deficiency and progressive lung dysfunction in premature newborns are largely supportive; even in term infants, alveolar dysgenesis and lung dysplasias represent serious immediate threats to life and cause long-term morbidity. Evidence is accumulating that the short-term benefits of available therapies may be outweighed by long-term detrimental effects on postnatal alveologenesis. Thus, the therapeutic implications of identifying a growth factor or molecular pathway that can be targeted to stimulate normal saccular and alveolar development are profound.
Supplementary materials related to this article can be found online at doi:10.1016/j.ydbio.2010.08.013.
